A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Study acronym: READY-AD
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 11 of 11 entries
    • Site details revised at 1 of 62 sites
  2. Study sites revised (62)v11
  3. Enrollment closed, study ongoing
    • Enrollment target: estimated 180 to confirmed 189
    • Site details revised at 62 of 62 sites
    v10
  4. Study sites revised (62)v9
  5. Trial sites expanded: 56 → 62 locationsv8
  6. Trial sites expanded: 52 → 56 locationsv7
  7. Trial sites expanded: 30 → 52 locationsv6
  8. Study sites: 14 to 30v5
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 14
    • Start date changed from estimate of Feb 13, 2026 to Jan 20, 2026
    v4
  10. 2 versions Re-verified since Dec 4, 2025, no change to tracked fieldsv2-v3
  11. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
Trial Details
NCT Number NCT07230860
Lead Sponsor Janssen Research & Development, LLC
Conditions
(from sponsor)		 Dermatitis, Atopic
Related terms Dermatitis, Atopic
Enrollment 189 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov